Beijing Tianshi Tongda Pharmaceuticals Technology

Beijing Tianshi Tongda Pharmaceuticals Technology is a clinical-stage biotechnology company headquartered in Beijing, China, dedicated to developing innovative therapies for metabolic and endocrine disorders. The company focuses on the design and optimization of multi-target peptide drugs, leveraging a proprietary discovery platform to address unmet medical needs. Its lead program, TS-001, is a dual agonist targeting the GLP-1 and GIP receptors, currently undergoing Phase 2 clinical trials for type 2 diabetes and obesity. TS-001 is designed to provide superior glycemic control and significant weight reduction compared to existing mono-agonist treatments. The company's pipeline also includes TS-002, a tri-agonist targeting GLP-1, GIP, and glucagon receptors for the treatment of nonalcoholic steatohepatitis (NASH). Tianshi Tongda is backed by leading venture capital firms and aims to become a global leader in the field of metabolic medicine.